AI Drug Discovery 2026: Isomorphic Labs Raises $2.1B as FDA Pilots Causal AI

2 articles Updated May 14, 2026 #ai #causal-ai #clinical-trials #demis-hassabis

Current state

Isomorphic Labs secures a $2.1B Series B to scale AI-driven drug discovery, while the FDA launches causal AI pilots aiming to cut clinical trial timelines by up to 40%.

What changed recently

FDA Pilots AI to Cut Drug and Medical Device Clinical Trial Times by Up to 40%
Isomorphic Labs Raises $2.1B Series B to Accelerate AI Drug Discovery

Key tensions

Optimistic case: AI Drug Discovery 2026: Isomorphic Labs Raises $2.1B as FDA Pilots Causal AI unlocks real, compounding leverage.

Skeptical case: reliability, cost, and control around AI Drug Discovery 2026: Isomorphic Labs Raises $2.1B as FDA Pilots Causal AI remain unresolved.

Signals to watch

Momentum and new coverage around “ai”
Momentum and new coverage around “causal-ai”
Momentum and new coverage around “clinical-trials”

Timeline

Latest

Sciences Reddit May 14, 2026 1 min read

FDA Pilots AI to Cut Drug and Medical Device Clinical Trial Times by Up to 40%

The FDA has launched a first-of-its-kind pilot using cloud-based causal AI to shorten drug and medical device clinical trial timelines by 20–40%. FDA Chief AI Officer Jeremy Walsh says the approach could also accelerate regulatory approval timelines.

#fda #clinical-trials #ai

Recent development

Sciences Reddit May 14, 2026 1 min read

Isomorphic Labs Raises $2.1B Series B to Accelerate AI Drug Discovery

Isomorphic Labs, the AI drug discovery company founded by DeepMind's Demis Hassabis, has raised $2.1 billion in Series B funding led by Thrive Capital. The round includes Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

#isomorphic-labs #drug-discovery #ai

Share: Long